Next-Generation Drug Development: Novel Modalities, AI Modeling, and Biomarkers
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 19
Special Issue Editor
Special Issue Information
Dear Colleagues,
Drug development is entering a new era shaped by the rise of innovative therapeutic modalities and the integration of advanced computational tools. Beyond traditional small molecules, biologics, antibody–drug conjugates (ADCs), nucleic acid-based drugs, and cell and gene therapies are transforming treatment strategies and presenting unique challenges for evaluation and translation. At the same time, artificial intelligence (AI), machine learning, and quantitative systems pharmacology are redefining pharmacokinetic/pharmacodynamic (PK/PD) modeling, improving prediction of efficacy and safety. The discovery and application of biomarkers and therapeutic targets further support precision medicine by guiding patient selection and treatment optimization.
This Special Issue of IJMS invites original research articles and reviews on cutting-edge approaches in drug development, spanning novel modalities, PK/PD modeling and simulation, AI-driven methods, and biomarker discovery to advance precision therapeutics.
Dr. Chun-Yi Wu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacokinetics
- PK/PD modeling
- biologics
- antibody–drug conjugates (ADCs)
- biomarkers
- artificial intelligence
- novel therapeutic modalities
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
